Our website is set to allow the use of cookies. For more information click here. If you are happy with cookies please click 'Proceed' or simply continue browsing.

Select a localised edition of our website

I am interested in Taylor Wessing LLP's expertise in this area in this country

  • legal expertise
  • sector experience
  • Banking & Finance
  • Commercial
  • Competition, EU & Trade
  • Corporate Crime & Fraud
  • Corporate, M&A and Capital Markets
  • Dispute Resolution
  • Employment, Pensions & Mobility
  • Environment, Public & Regulatory
  • IP/IT
  • Private Client
  • Projects
  • Real Estate & Construction
  • Restructuring & Corporate Recovery
  • Tax
  • Automotive
  • Business & Professional Services
  • Consumer & Retail
  • Energy
  • Financial Institutions
  • Healthcare
  • Hotels & Leisure
  • Insurance
  • Life Sciences
  • Logistics & Transport
  • Manufacturing & Industrials
  • Private Wealth
  • Public Services & Education
  • Real Estate & Infrastructure
  • Technology, Media & Communications
  • Austria
  • Belgium
  • China
  • Czech Republic
  • France
  • Germany
  • Hungary
  • Indonesia
  • Netherlands
  • Poland
  • Singapore
  • Slovakia
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States

Matthew Royle, Tim Worden and Paul England of Taylor Wessing discuss the issues raised by Brexit for the authorisation of medicinal products and medical devices, and how the available exclusivity rights for these products may be affected.

${expertFirstname} ${expertSurname}

${expertPracticearea}
${expertJobtitle} | ${expertOffice}

{{if expertProfileimage!="99999999"}}
{{/if}}
${expertTelephone}
${expertFax}

Next Event

${date}

${name}

${city}